UV Spectrophotometric Method for the Estimation of Tolvaptan in Bulk and Pharmaceutical Formulations

 

K. Vijaya Sri*, S. Sruthi and  l.D. Srinivas

Department of  Pharmaceutical  Analysis,  Malla Reddy College of  Pharmacy,

Maisammaguda, Secunderabad-500 014, Andhra Pradesh, India

*Corresponding Author E-mail: vijayasree_2002@yahoo.co.in

 

ABSTRACT:

The main objective was to develop and validate the UV-spectrophotometric method for the estimation of tolvaptan in bulk and pharmaceutical formulations as per ICH guidelines. The initial stock solution of Tolvaptan was prepared in acetonitrile. The λmax of tolvaptan was found to be 267 nm  it was proved  linearity in the concentration range 1–10  μg/ml with a correlation coefficient value of 0.999. The accuracy studies of proposed  method was performed at three different levels, i.e., 50%, 100%, and 150% and recovery was found to be in the range of 100.4%.The limit of detection (LOD) and limit of quantification (LOQ) were found to be 0.34  and 0.94  µg/ml, respectively.The % RSD less than 2 which indicates the accuracy and precise of the method. The above method was a rapid tool for routine analysis of  tolvaptan  in the bulk and in the pharmaceutical dosage form.

                                                                            

KEYWORDS: Tolvaptan, UV Spectroscopy, Development, Validation and Pharmaceutical formulation.

 

 


INTRODUCTION:

Tolvaptan is chemically  4'-[7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin1-yl)carbonyl]-o-tolu-m-toluidide. It is a selective vasopressin v2 receptor antogonist1. When taken orally tolvaptan antogonise the effect of vasopressin and causes an increase in urine water excretion that results in an increase in free water clearance, a decrease in urine osmolarity and a resulting increase in serum sodium concentrations. 2

 

Figure No.1 Structure of  Tolvaptan

 

It is a diuretic agent. It is used to treat hyponatraemia associated with congestive heart failure, cirrhosis and syndrome of inappropriate antidiuretic hormone(SIADH) it is soluble in methanol and benzyl alcohol and insoluble in water and hexane at a wide range of pH. 2

 

Literature review reveals that there is  UV method, 3,4  few methods based on HPLC5,6, UPLC7 and LC-MS/MS8 for its estimation in bulk and dosage forms. The present work describes the development and validation of UV spectrophotometric method, which can quantify the rilpivirine hydrochloride.  An attempt was made to develop a simple, accurate, precise and rapid spectrophotometric method for the estimation of   Tolvaptan  in bulk and pharmaceutical dosage form. The method was validated as per International conference on Harmonization (ICH) guidelines.9,10 The present work describes the development and validation of UV spectrophotometric method, which can quantify the Tolvaptan. An attempt was made to develop a simple, accurate, precise and rapid spectrophotometric method for the estimation of   Tolvaptan in bulk and pharmaceutical dosage form. The method was validated as per International conference on Harmonization (ICH) guidelines.

 

MATERIALS AND METHODS:

Materials

Tolvaptan was obtained as gift sample from Hetreo Laboratories Ltd. (Hyderabad, A.P, India). Acetonitrile  All chemicals used were of analytical grade and purchased from Qualigens Fine Chemicals, Mumbai, India. 

 

Instruments

A double beam UV-VIS spectrophotometer (UV-1800, Shimadzu, Japan) connected to computer loaded with   spectra manager software UV Probe was employed with   spectral bandwidth of 1nm and wavelength accuracy of ± 0.3 nm with a pair of 10 mm matched quartz cells.

 

Preparation of Standard stock solution of Tolvaptan

An accurately weighed quantity of Tolvaptan 50mg was transferred to 50ml volumetric flask, dissolved in 20ml , the final volume was made with acetonitrile to obtain standard solution having concentration of 1000 μg/mL. 1ml of this solution was transferred to 10ml volumetric flask, volume was made with acetonitrile. It gives 100 µg/ml. These stock solutions were used to prepare further dilutions.

 

Selection of wavelength for analysis of  Tolvaptan

Appropriate volume 0.1 ml of standard stock solution of  tolvaptan was transferred into a 10 ml volumetric flask, diluted to a mark with acetonitrile to give concentration of  1 μg/ml. The resulting solution was scanned in the UV range (200–400 nm).

 

VALIDATION OF PROPOSED METHOD:

The method was validated according to ICH guidelines in order to determine the linearity, precision, accuracy and ruggedness of the method.

 

Linearity

Linearity was assessed by performing  measurement at several analyte concentration varying quantities of stock solution was diluted with the acetonitrile  to give 0. 25, 0.5, 1, 1.5, 2, 2.5 and 3 µg/ml of Tolvaptan. The calibration curve was obtained by plotting absorbance against concentration (μg/ml).

 

Repeatability

Repeatability was determined by preparing six replicates of 1 µg/ml of Tolvaptan  and the absorbance was measured at 280nm.

 

Precision

Precision studies were carried out to ascertain the reproducibility of the proposed method. Intraday precision study was carried out by preparing drug solution of three different concentrations (0.5, 1 and 2 µg/ml of Tolvaptan) and analyzing it at three different times in a day. Interday precision study was carried out by preparing drug solution of three different concentrations (0.5, 1 and 2 µg/ml of Tolvaptan) and analyzing it at three different days.

 

Accuracy

Accuracy of the proposed method was determined using recovery studies. The recovery studies were carried out by adding different amounts (50%, 100%, and 150%) of the pure drug to the pre-analysed formulation. The solutions were prepared in triplicates and the % recovery was calculated.

 

Limit of Detection and Limit of Quantitation:

The parameters LOD and LOQ were determined on the basis of response and slope of the regression equation. The limit of detection (LOD) and the limit of quantitation (LOQ) of the drug were derived by calculating the signal-to-noise ratio (S/N, i.e., 3.3 for LOD and 10 for LOQ) using the following equations designated by International Conference on Harmonization (ICH) guidelines.

 

LOD = 3.3 × σ/S                                    

LOQ = 10 × σ/S

Where σ = the standard deviation of the response and S = slope of the calibration curve

 

Ruggedness Studies

Ruggedness studies were performed by preparing three replicates of 1µg/ml of Tolvaptan, analysing by two different analyst and on two different instruments and the results are reported as %RSD.

 

Application of the proposed method for pharmaceutical formulation

The solution was filtered through Whatman filter paper No.41. 0.5 ml this solution was  transferred to 10ml volumetric flask and final volume was made with acetonotrile. It gives 0.5µg/ml. It was scanned on a spectrophotometer in the UV range 200–400 nm. The spectrum was recorded at 267 nm against blank solution of acetonitrile. Determine the amount of % Tolvaptan in tablet according to the following formula.

 

                    AT x WS × Sample D.F x Average Weight

% Assay   =--------------------------------------------------- x PR

             AR x Standard D.F x WT× LA

 

Where,

WS =  weight of standard;

WT = weight of sample

Where,

AT = Absorbance of Tolvaptan in the test solution,

AR= Absorbance of Tolvaptan in the standard solution, Std.

DF=Standard dilution factor, Sample D.F = Sample dilution factor PR = Purity of working standard [%], LA = Labeled amount of Tolvaptan

 

 


RESULTS AND DISCUSSION:

In spectrum Tolvaptan shows maximum   absorbance at 267 nm shown in figure 2.

 

Figure No. 2. Absorption Spectrum of Tolvaptan

 

Method validation

The proposed method was validated as per ICH guidelines. The solutions of the drugs were prepared as per the earlier adopted procedure given in the experiment.

 

Linearity

Standard solutions of  Tolvaptan in the concentration range of 0.25 to 3 µg/ml were observed in UV spectroscopy at different wave lengths.

 

A graph of absorbance (on Y-axis) versus concentration (on X-axis) was plotted and  calibration graph was shown in  Figure  2 and 3. The regression equation was found to be  Y=0.148x+0.075 , Correlation coefficient was 0.999.

 

Repeatability

Repeatability was determined by analyzing 1 μg/ml concentration of tolvaptan for six times  with % RSD < 2 which shown in table  no 1.                                

 

Table No. 1 Repeatability studies of  Tolvaptan

Concentration

[µg/ml]

Absorbance

at 267 nm

Absorbance  Mean

SD

%RSD

6

0.641

 

 

0.646

 

 

0.008

 

 

1.295

6

0.657

6

0.650

6

0.651

6

0.636

6

0.638

 

Precision

The precision of the developed method was expressed in terms of % relative standard deviation (% RSD). These results show reproducibility of the assay. The % RSD values found to be less than 2 that indicate this method precise for the determination of the pure form.  The inter and intraday precision  results were mentioned in Table no.2.

 

Figure No. 3  Calibration curve of  Tolvaptan  at  267nm

 

 

Table No.2  Intraday and Interday precision of  Tolvaptan

Conc.

(µg/ml)

Intraday Precision

Interday Precision

Absorbance mean± S.D. (n=3)

%RSD

Absorbance mean± S.D. (n=3)

%RSD

2

0.197 ± 0.001

1.015

 

0.196 ± 0.001

 

0.510

 

6

0.626 ± 0.006

0.962

 

0.627 ± 0.002

 

0.421

 

10

1.032 ± 0.004

0.477

 

1.033 ± 0.003

 

0.339

 

 

Accuracy

Accuracy shall be determined by performing  recovery studies at 3 levels in which known amount of analyte shall be added and recovery shall be carried out in three replicates of each concentration level and the % recovery was calculated. The mean recovery was found between 100-101 % and %RSD between 0.7-1.0 The results are shown in Table No. 3.

 

 


Table No. 3  Recovery studies of  Tolvaptan

Spiked level (%)

Formulation

Conc (µg/ml)

Pure Drug Conc (µg/ml)

Amount Conc recovered (µg/ml)

% Recovery

% Mean recovery

SD

%RSD

 

50

2

1

3.01

100.6

99.24±1.311

0.32

2

1

2.97

99.0

2

1

2.94

98.0

 

100

2

2

4.02

100.7

100.24±0.491

0.490

2

2

3.99

99.7

2

2

4.00

100.2

 

150

 

2

3

4.96

99.2

99.74±0.487

0.488

2

3

4.99

99.8

2

3

5.00

100.19


Limit of Detection and Limit of Quantitation

The parameters LOD and LOQ were determined on the basis of response and slope of the regression equation. LOD and LOQ values are 0.34 and 0.94 µg/ml.

 

Ruggedness Studies

This study was performed by analyzing 4 µg/ml of Tolvaptan by two different analysts and on two instruments, results of the study were given in Table no. 4 and % RSD obtained was less than two which is within the acceptance limits.

 

Table No. 4 Ruggedness of Tolvaptan

Parameter

Conc. (µg/ml)

Absorbance

Absorbance mean

± S.D. (n=3)

%RSD

 

Different Analyst

 

4

 

0.405

0.407±

0.0025

 

0.61

0.41

0.407

 

Different instrument

 

4

0.404

0.408±

0.0036

 

0.88

0.409

0.411

 

 

Application of the Proposed Method for Pharmaceutical Formulation

The percentage recovery for Tolvaptan  tablet formulation was found to be 99.6 -101.06 % enlisted in table no.5. The results for assay are within acceptable limit.

 

Table no. 5 Assay   of  Tolvaptan

Labelled amount (mg)

Amount found (mg)

% Purity

Mean % purity ± SD(n=3)

%RSD

15

15.07

100.49

 

100.16±0.788

 

15

15.10

100.73

0.787

15

14.88

99.26

 

 

The summary of proposed method results are shown in table no 6.

 

Table no 6: Summary of Validated parameters

Parameters

Method

λmax (nm)

267

Beers law limit (µg/ml)

1-10

Correlation coefficient (r2)

0.999

Molar absorptivity (L mol-1 cm-2)

3.41×104

Regression equation (y=mx+c)

Y=0.1036x+0.0006

Slope(m)

0.1036

Intercept(c)

0.0006

accuracy

99.24-100.24

precision

0.339-1.015

LOD (µg/ml)

0.310

LOQ (µg/ml)

0.941

 

CONCLUSION:

The developed UV Spectrophotometric method was found to be simple, economic, easy, accurate, precise, reproducible and highly sensitive and can be used for routine estimation of Tolvaptan in bulk and formulations.

 

ACKNOWLEDGEMENTS:

The authors are grateful to, Mallareddy College of  Pharmacy  for  providing necessary research facilities to carry out the research  work and to hetero drugs, India for providing the gift sample of the drug.

REFERENCES:

1.        Australian public assessment report for tolvaptan : 2012

2.        USFDA : Drug safety communications : 2013

3.        Murugan S, Pavan Kumar N, Kiran Kumar C, Syam Sundar V, Harika S and Anusha P; Method development and validation for dissolution method of tolvaptan in bulk and tablet dosage form by UV–Spectrophotometry. Indian journal of pharmaceutical science and research. 2013, 3(1), 17-19.

4.        Chaudhari BG, Patel C; Development and validation of UV spectroscopic method for the estimation of tolvaptan in bulk and tablet dosage form. International Journal for Pharmaceutical Research Scholors. 2012 Vol – 1(3)41-45

5.        B. Prathyusha, B. Shirisha, N. Sriram, N. Ramathilagam; Analytical method development and validation of tolvaptan in bulk and tablet dosage form by RP-HPLC. 2013, 2(4)32-36

6.        V. Kalyan Chakravarthy, D. Gowri Shankar; Development and validation of     RP – HPLC method for estimation of tolvaptan in bulk and its pharmaceutical formulation. Rasayan J. Chem. 2011, 4(1), 1165 – 171.

7.        Lanka A. Ramprasad,  J.V.L.N.S Rao, Srinivasu Pamidi, Vara Prasad J, Naga Raju D; Impurity profiling of tolvaptan tablets using new stability indicating UPLC method. International Research Journal of Pharmacy. 2012 , 3(11).21-25

8.        Pei. Q, Bikui Zhang, Hongyi Tan, Lihua Liv, Mi Luo; Development and validation of an LC-MS/MS method for the determination of tolvaptan in human plasma and its application to a pharmacokinetic study. Journal of Chromatography. B. 2013, Vol. 913-914, pages. 84-89

9.        Validation of analytical procedures  text and methodology Q2 (R1)

10.     ICH Harmonized Tripartite Guideline, ICH Q2B (May 1997), Validation of analytical procedures: methodology

 

 

 

 

Received on 29.08.2014         Modified on 09.09.2014

Accepted on 13.09.2014         © AJRC All right reserved

Asian J. Research Chem. 7(9): September 2014; Page 773-776